Cullinan Oncology (United States)

Recent papers from Cullinan Oncology (United States)

1. Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.Journal of Clinical Oncology · 2024
2. CD19-directed T cell–engaging antibodies for the treatment of autoimmune diseaseThe Journal of Experimental Medicine · 2024
3. Abstract 5297: CLN-619, a clinical stage MICA/B-specific hIgG1 monoclonal antibody, engages multiple immune effector cells to promote anti-tumor activityCancer Research · 2024
4. CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expressionJournal for ImmunoTherapy of Cancer · 2023
5. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsJournal of Clinical Oncology · 2023
6. Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptorsmAbs · 2023
7. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunitiesCurrent Opinion in Oncology · 2022